Towa Pharmaceutical Co Ltd

Towa Pharmaceutical maintains a capital structure with a debt-to-equity ratio of 1.35, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 2.81, suggesting it has sufficient short-term assets to cover its liabilities. However, the firm's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, Towa Pharmaceutical reports a return on equity (ROE) of 11.06% and a return on assets (ROA) of 4.03%. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key indicators of financial performance. The company's operating margin is 9.41% (calculated from operating income of ¥24.45 billion on revenue of ¥259.59 billion), which is a strong indicator of operational efficiency. Geographically, Towa Pharmaceutical's revenue is heavily concentrated in Japan, with no significant international operations disclosed in the available data. This concentration may expose the company to domestic economic and regulatory risks, which could affect its revenue stability. The company's growth trajectory is modest, with no specific revenue growth projections provided in the input data. However, the firm's operating cash flow of ¥23.61 billion and free cash flow of ¥4.91 billion suggest a capacity to fund operations and potentially invest in future growth. Towa Pharmaceutical faces a medium liquidity risk, as noted in the risk assessment, and a low dilution risk. The company has not issued additional shares recently, and there is no indication of dilution pressure in the near term. The firm's capital structure remains stable, with no significant adjustments to its valuation metrics. Recent events, including analyst estimates and price targets, indicate a generally positive outlook from the investment community. The mean price target of ¥4,816.67 and a mean recommendation of 2.00 (on a scale from 1 to 5) suggest that analysts view the stock as a buy or hold, with a median price target of ¥4,800.00.